Based on the group median 2−ΔCt values, NCL expression in pre-B ALL vs. controls was ~1.48-fold lower (≈ 1.5-fold), in neuroblastoma vs. pre-B ALL, it was 2.21-fold lower (≈ 2.2-fold), and in neuroblastoma vs. controls, it was 3.27-fold lower (≈ 3.3-fold). Here, NUCLEOLIN is linked to acute lymphoblastic leukemia.